Neoplasms

Digestive System Diseases

All Conditions

Skin and Connective Tissue Diseases

Respiratory Tract (Lung and Bronchial) Diseases

Urinary Tract, Sexual Organs, and Pregnancy Conditions

Gland and Hormone Related Diseases

Blood and Lymph Conditions

Immune System Diseases

Ear, Nose, and Throat Diseases

Rare Diseases

Esophageal Neoplasms

Carcinoma

Breast Neoplasms

Carcinoma, Non-Small-Cell Lung

Prostatic Neoplasms

Thyroid Neoplasms

Thyroid Diseases

Osteosarcoma

Head and Neck Neoplasms

Sarcoma

Carcinoma, Renal Cell

Carcinoma, Small Cell

Lung Neoplasms

Ovarian Neoplasms

Carcinoma, Ovarian Epithelial

Liposarcoma

Lymphoma

Lymphoma, T-Cell

Lymphoma, T-Cell, Peripheral

Urinary Bladder Neoplasms

Hodgkin Disease

Mesothelioma

Mesothelioma, Malignant

Lymphoma, B-Cell

Chondrosarcoma

Fibrosarcoma

Hemangiosarcoma

Kidney Neoplasms

Leiomyosarcoma

Adenoma, Pleomorphic

Parathyroid Neoplasms

Otorhinolaryngologic Neoplasms

Adenosarcoma

Mixed Tumor, Mesodermal

Neoplasms by Histologic Type

Lymphoproliferative Disorders

Lymphatic Diseases

Immunoproliferative Disorders

Esophageal Cancer

Ovarian Cancer

B-cell Lymphoma

Renal Cell Carcinoma

Ovarian Epithelial Cancer

Soft Tissue Sarcoma

Lymphosarcoma

Peripheral T-cell Lymphoma

Hodgkin Lymphoma

Malignant Mesothelioma

Antineoplastic Agents

All Drugs and Chemicals

Belinostat

Parathyroid Hormone

Histone Deacetylase Inhibitors

Enzyme Inhibitors

oral belinostat dosed once or twice daily at continuous and discontinuous dosing schedules.

oral belinostat

enquiries@topotarget.com

This is a Phase I dose escalation study of PXD101 administered orally. Oral belinostat will be given once or twice daily at various dosing schedules to patients with solid tumors. Doses will be escalated until the maximum tolerated dose (MTD) is identified. In parallel, a cohort of lymphoma patients will be given oral belinostat on a discontinuous once daily dosing schedule.

Study of Oral PXD101 in Patients With Advanced Solid Tumors or Lymphoma

Open Label, Dose Escalation Trial of Oral PXD101 in Patients With Advanced Solid Tumors

Spectrum Pharmaceuticals, Inc

Valerio Therapeutics

Symptoms and General Pathology

Mouth and Tooth Diseases

Syndrome

Facies

Solitary Pulmonary Nodule

Histiocytoma, Malignant Fibrous

Mouth Neoplasms

Carcinosarcoma

Mixed Tumor, Mullerian

Histiocytoma

Carcinoma, Bronchogenic

Phyllodes Tumor

Hemangioma

Pancoast Syndrome

Lymphangiosarcoma

Myosarcoma

Tracheal Neoplasms

Facial Neoplasms

Oral Cancer

Malignant Mixed Mullerian Tumor

Androgens

Fluorouracil

Antimetabolites

Immunosuppressive Agents

Immunologic Factors

300, 600, or 1000 mg/m2 belinostat IV for 5 days every 21 days starting with cycle 1

belinostat

250, 500, 750, or 1000 mg/m2/d of 5-FU starting with cycle 2 onwards in combination with belinostat. Starting on day 2, 5-FU is administered as a continuous 96 hour infusion.

5-Fluorouracil (5-FU)

Topotarget A/S

This is a study to assess the combination of PXD101 and 5-Fluorouracil (5-FU)in patients with advanced solid tumors. The primary goal of the study is to understand the safety, anti-tumor activity, and how the study drug behaves within the body when given with 5-Fluorouracil (5-FU).

Study of PXD101 Alone and in Combination With 5-Fluorouracil (5-FU) in Patients With Advanced Solid Tumors

A Phase I Safety, Pharmacodynamic, Anti-Tumor Activity, and Pharmacokinetic Study of PXD101 Alone and in Combination With 5-Fluorouracil in Patients With Advanced Solid Tumors

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Study of Oral PXD101 in Patients With Advanced Solid Tumors or Lymphoma	NCT00413075	Solid Tumor Lymphoma	oral belinostat	18 Years -	Valerio Therapeutics
Study of PXD101 Alone and in Combination With 5-Fluorouracil (5-FU) in Patients With Advanced Solid Tumors	NCT00413322	Tumor	belinostat 5-Fluorouracil ...	18 Years -	Valerio Therapeutics
Study of Oral PXD101 in Patients With Advanced Solid Tumors or Lymphoma	NCT00413075	Solid Tumor Lymphoma	oral belinostat	18 Years -	Valerio Therapeutics
Study of PXD101 Alone and in Combination With 5-Fluorouracil (5-FU) in Patients With Advanced Solid Tumors	NCT00413322	Tumor	belinostat 5-Fluorouracil ...	18 Years -	Valerio Therapeutics
Study of PXD101 Alone and in Combination With 5-Fluorouracil (5-FU) in Patients With Advanced Solid Tumors	NCT00413322	Tumor	belinostat 5-Fluorouracil ...	18 Years -	Valerio Therapeutics

Spots Global Cancer Trial Database for mixed tumor, mesodermal